Ipsen Sa S/Adr (IPSEY) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Ipsen Sa.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.503 -- 00:00:06.251 Hello and welcome to Ibsen's conference call and webcast for the first quarter 2025 00:00:06.251 -- 00:00:12.216 results. I'll now hand you over to David Lowe, Ibsen's CEO. 00:00:12.259 -- 00:00:17.246 Thank you and hello everyone. I'm delighted to welcome you to our Q1 sales presentation 00:00:17.246 -- 00:00:20.650 this afternoon, which can also be found on Ibsen.com. 00:00:20.650 -- 00:00:25.757 Please turn to slide two. Please take note of our forward-looking statements, which outline 00:00:25.757 -- 00:00:29.528 the routine risks and uncertainties contained within this presentation. 00:00:29.528 -- 00:00:33.296 Also, any of my commentary on growth will be based on constant exchange rates. 00:00:33.296 -- 00:00:35.801 Please turn to slide three. 00:00:35.801 -- 00:00:39.308 I'm going to take you through our sales performance of the first quarter and provide 00:00:39.308 -- 00:00:44.298 you with a business update after which our CFO, Emmerich Le Chatelier, will join me for 00:00:44.298 -- 00:00:48.506 the question and answer session. Let's begin by looking at today's highlights. 00:00:48.506 -- 00:00:50.892 Please turn to slide four. 00:00:50.892 -- 00:00:54.836 We continued to deliver a strong top-line growth in quarter one. 00:00:54.836 -- 00:00:57.579 Total sales grew by 11.6%, 00:00:57.579 -- 00:01:02.204 driven by all three therapeutic areas, and including an increase in contribution from 00:01:02.204 -- 00:01:07.369 my Corvo and Bill Bay. Since the beginning of the year, we have made good progress 00:01:07.369 -- 00:01:12.475 with our pipeline, including the EMA regulatory submission of tovorafenib 00:01:12.475 -- 00:01:17.740 for pediatric low-grade glioma, the entry in phase one of a third-generation 00:01:17.740 -- 00:0...